Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer

NCT06600906 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT06600906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06600906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer
Lead sponsor
University of California, San Francisco
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2024
Completion date
September 1, 2032
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic ductal adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma